Autologous stem cell therapy - Biotech Holdings

Drug Profile

Autologous stem cell therapy - Biotech Holdings

Alternative Names: Microbiome optimized autologous stem cells - Biotech Holdings

Latest Information Update: 07 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biotech Holdings
  • Class Antineoplastics; Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Peripheral vascular disorders

Most Recent Events

  • 07 Jul 2017 Clinical trials in Peripheral vascular disorders in USA (Parenteral)
  • 07 Jul 2017 Adverse events and efficacy data from a clinical trial in Peripheral vascular disorders (associated with critical limb ischaemia) released by Biotech Holdings
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top